Literature DB >> 27272

Factors limiting the rate of termination of the neuromuscular blocking action of fazadinium dibromide.

M B Tyers.   

Abstract

1 Reasons for the termination of the neuromuscular blocking action of fazadinium dibromide have been investigated. 2 In the anaesthetized cat, maximum neuromuscular block of tibialis anterior muscle twitches following rapid intravenous injection of fazadinium was obtained as the injection bolus passed through the muscle, indicating the fazadinium very readily crosses capillary membranes. 3. The half-life of plasma clearance of fazadinium was about 1 min in both cat and man, despite a 10 fold difference in duration of action in these species. Plasma samples were bioassayed for neuromuscular blocking activity on an isolated, superfused phrenic nerve-diaphragm preparation of the rat. 4 In the anaesthetized cat, occlusion of the renal or hepatic circulations did not prolong the neuromuscular blocking action of single doses of fazadinium. Repeated doses accumulated slowly when the hepatic circulation was occluded but not when the renal circulation was occluded. 5 Fazadinium is eliminated from the body by both the liver and kidneys but the rates of these processes are insufficient to account for the initial rapid plasma clearance. 6 The rate-limiting step for the termination of the neuromuscular blocking action of fazadinium is most likely to be the rate of drug-receptor dissociation

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 27272      PMCID: PMC1668400          DOI: 10.1111/j.1476-5381.1978.tb09759.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  18 in total

1.  The pharmacology of neuromuscular blocking agents in man.

Authors:  F F FOLDES
Journal:  Clin Pharmacol Ther       Date:  1960 May-Jun       Impact factor: 6.875

2.  A new theory of the termination of action of the muscle relaxants.

Authors:  S A Feldman; M F Tyrrell
Journal:  Proc R Soc Med       Date:  1970-07

3.  An azobis-arylimidazo-pyridinium derivative: a rapidly acting non-depolarising muscle-relaxant. Clinical study.

Authors:  B R Simpson; L Strunin; T M Savege; B Walton; E I Foley; M P Maxwell; L A Ross; D M Harris
Journal:  Lancet       Date:  1972-03-04       Impact factor: 79.321

4.  The pharmacology of AH8165: a rapid-acting, short-lasting, competitive neuromuscular blocking drug.

Authors:  R T Brittain; M B Tyers
Journal:  Br J Anaesth       Date:  1973-08       Impact factor: 9.166

5.  A novel monoquaternary neuromuscular blocking agent.

Authors:  D G Bamford; D F Biggs; P Chaplen; M Davis; J Maconochie
Journal:  Experientia       Date:  1972-09-15

6.  Some effects of the steroidal muscle relaxant, dacuronium bromide, in anaesthetized patients.

Authors:  J Norman; R L Katz
Journal:  Br J Anaesth       Date:  1971-04       Impact factor: 9.166

7.  The metabolism and elimination of d-tubocurarine-H3.

Authors:  E N Cohen; H W Brewer; D Smith
Journal:  Anesthesiology       Date:  1967 Mar-Apr       Impact factor: 7.892

8.  Rapid intubation with fazadinium and suxamethonium.

Authors:  S Mehta; K Lewin; K Fidler
Journal:  Can Anaesth Soc J       Date:  1977-03

9.  The effect of renal failure on the disposition and neuromuscular blocking action of pancuronium bromide.

Authors:  A A Somogyi; C A Shanks; E J Triggs
Journal:  Eur J Clin Pharmacol       Date:  1977-08-17       Impact factor: 2.953

10.  The margin of safety of neuromuscular transmission.

Authors:  W D Paton; D R Waud
Journal:  J Physiol       Date:  1967-07       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.